Illustration of a doctor discussing positive kidney treatment results with a patient using digital graphs.
Imagen generada por IA

La finerenona ralentiza el deterioro renal en un ensayo de ERC no diabética; un análisis combinado sugiere beneficios más amplios en la ERC

Imagen generada por IA
Verificado por hechos
Español

Nuevos datos presentados en el 63.º Congreso de la Asociación Renal Europea en Glasgow y publicados en tres revistas médicas importantes hallaron que la finerenona ralentizó el deterioro de la función renal en adultos con enfermedad renal crónica (ERC) sin diabetes y redujo el riesgo de un desenlace combinado renal y cardiovascular. Un análisis combinado por separado, que integró resultados de varios estudios sobre la finerenona, también reportó menos eventos renales y de insuficiencia cardíaca en una población con ERC más amplia.

Los investigadores informaron de los resultados en el 63.º Congreso de la Asociación Renal Europea (ERA, por sus siglas en inglés) en Glasgow, Escocia, con publicaciones simultáneas vinculadas a las presentaciones en The New England Journal of Medicine, JAMA y The Lancet.

Qué dice la gente

Las reacciones iniciales en X destacan los resultados positivos del ensayo FIND-CKD, que muestran que la finerenona ralentiza el deterioro de la eTFG en pacientes con ERC no diabética, con una reducción del riesgo del 23% en eventos renales y cardiovasculares, así como beneficios similares en análisis combinados en poblaciones con ERC más amplias. Los profesionales médicos y las revistas expresan entusiasmo por las indicaciones ampliadas más allá de la diabetes.

Artículos relacionados

Clinical illustration of nurse giving single-dose zilebesiran injection to hypertension patient, with blood pressure monitor showing reduction from KARDIA-2 trial results.
Imagen generada por IA

Single-dose zilebesiran as add-on therapy lowers systolic blood pressure in KARDIA-2 trial

Reportado por IA Imagen generada por IA Verificado por hechos

A single, under-the-skin dose of the investigational RNA-interference drug zilebesiran lowered blood pressure when added to standard therapy in adults whose hypertension remained uncontrolled, according to results from the global Phase 2 KARDIA-2 trial of 663 participants published in JAMA.

FDA approves Travere Therapeutics' FILSPARI for FSGS

The U.S. Food and Drug Administration approved FILSPARI, developed by Travere Therapeutics, as the first medicine for focal segmental glomerulosclerosis (FSGS). Travere announced the approval on April 13, 2026. Company executives held a business update conference call that evening to discuss the milestone.

Pemafibrate and telmisartan cut liver fat in MASLD animal models, study suggests

Reportado por IA Verificado por hechos

Researchers in Barcelona report that the lipid drug pemafibrate and the blood-pressure medicine telmisartan reduced diet-induced liver fat in rats and in a zebrafish model of fatty liver disease, with a half-dose combination performing as well as full doses of either drug alone. The work, published in Pharmacological Research, also describes a role for the PCK1 protein in telmisartan’s liver effects and argues that clinical trials would be needed to confirm any benefit in people.

Salud

New drug Daraxonrasib nearly doubles survival in pancreatic cancer trial

Salud

Enlicitide pill reduces LDL cholesterol by 60% in phase 3 trial

Salud

Longevity startup doses first patient in vision loss trial

Trial finds metformin may let adults with type 1 diabetes use less insulin without improving insulin resistance

A randomized, placebo-controlled trial led by Australia’s Garvan Institute of Medical Research found that metformin, a long-used and low-cost drug for type 2 diabetes, did not improve clamp-measured insulin resistance in adults with type 1 diabetes but was associated with roughly 12% lower insulin requirements while blood sugar measures remained broadly unchanged.

Evolocumab reduces heart attack risk by 31% in high-risk diabetes patients

Reportado por IA

Researchers from Mass General Brigham found that the cholesterol drug evolocumab cuts the risk of first-time major cardiovascular events by 31% in high-risk patients with diabetes who lack diagnosed atherosclerosis. The results, from a subgroup analysis of the VESALIUS-CV trial, were presented at the American College of Cardiology's Annual Scientific Session and published in JAMA. Patients on the drug saw LDL cholesterol levels drop significantly alongside standard treatments.

28 de mayo de 2026 16:21

Gene-editing drug slashes bad cholesterol 62 percent in trial

25 de mayo de 2026 16:39

Study finds beta blockers offer no benefit after uncomplicated heart attacks

21 de mayo de 2026 22:41

Review finds GLP-1 drugs linked to lower risk of heart attack, stroke and death in high-risk patients

6 de mayo de 2026 06:50

Innovative Cape Town clinic boosts outcomes for young kidney patients

1 de mayo de 2026 10:29

Smart water bottles and coaching increased hydration but did not cut kidney stone recurrences, trial finds

15 de abril de 2026 12:08

Hitting urate targets with gout-lowering therapy is linked to lower cardiovascular risk in large UK study

9 de abril de 2026 23:54

Vanderbilt study finds muscle loss with weight loss drugs and surgery

Este sitio web utiliza cookies

Utilizamos cookies para análisis con el fin de mejorar nuestro sitio. Lee nuestra política de privacidad para más información.
Rechazar